Edition:
United Kingdom

People: Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.57USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$8.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
436,460
52-wk High
$15.47
52-wk Low
$6.00

Griffith, Christopher 

Mr. Christopher M. Griffith is Chief Business and Strategy Officer of the Company. He founded our company in August 2010 and has served as our Chief Business and Strategy Officer since May 2018, after previously serving as our Senior Vice President of Corporate Development and Strategy since January 2017, Vice President of Corporate Development and Strategy from August 2011 to January 2017, and our Head of Corporate Development and Strategy from September 2010 to August 2011. From July 2005 to September 2010, Mr. Griffith worked in corporate development at Gilead Sciences, Inc., a research-based biopharmaceutical company, most recently as Associate Director of Corporate Development. From May 2004 to August 2004, Mr. Griffith worked in the bio-oncology strategy group at Genentech, Inc., a biotechnology company (“Genentech”). From 2001 to 2003, Mr. Griffith worked at Bay City Capital. Mr. Griffith received B.S. and M.S. degrees in biological sciences from Stanford University and an M.B.A. degree from Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 738,354
Restricted Stock Award, USD 94,800
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 833,154

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 9,121 277,332.00
Name Fiscal Year Total

Thomas Wiggans

4,371,180

Luis Pena

2,519,500

Andrew Guggenhime

2,360,030

Christopher Horan

2,358,110

Christopher Griffith

833,154

Lori Lyons-Williams

2,704,630
As Of  31 Dec 2018